XRO:ASXXero Limited Analysis
Data as of 2026-03-14 - not real-time
A$80.53
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Xero (XRO) is trading at AUD 80.53, just above its 20‑day SMA of 80.13 but well below the 50‑day (90.23) and 200‑day (140.37) averages, indicating a short‑term bounce within a longer‑term downtrend. The RSI sits at 45, suggesting neutral momentum, while the MACD histogram is positive (0.92) despite the MACD line being below the signal, hinting at a potential bullish reversal. Support at 71.45 and resistance near 89.47 frame the current price, and the stock has recently posted a 12% recovery, which aligns with the optimistic tone in recent Motley Fool commentary. However, volatility remains extremely high at 79% over the past 30 days and volume is decreasing, underscoring a fragile price environment. On the fundamentals side, revenue is growing at 20% YoY with an impressive 89% gross margin and solid operating cash flow, but the valuation is stretched: a trailing P/E of 54 versus an industry average of 34 and a forward P/E of 63. The DCF‑derived fair value of AUD 124.48 implies an upside of roughly 90%, far exceeding current market pricing. While the company’s balance sheet is strong, with cash exceeding debt by a factor of three, the lack of dividend and a modest ROE of 8% limit income‑oriented appeal. The beta of 0.69 points to lower systematic risk, but the tech‑software sector carries inherent high growth risk. In summary, XRO presents a compelling undervalued narrative driven by strong margins and growth, yet the high volatility and bearish medium‑term trend warrant cautious positioning.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above 20‑day SMA and near support
- Positive MACD histogram suggesting early reversal
- High short‑term volatility and decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth of 20% with 89% gross margin
- DCF fair value indicating ~90% upside
- Improving sentiment after recent 12% price recovery
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong cash position relative to debt
- Sustained high operating margins and expanding product suite
- Undervalued relative to DCF and growth prospects despite high P/E
Key Metrics & Analysis
Financial Health
Revenue Growth19.90%
Profit Margin11.63%
P/E Ratio54.0
ROE8.29%
ROA4.29%
Debt/Equity29.52
P/B Ratio3.4
Op. Cash FlowA$964.5M
Free Cash FlowA$590.7M
Industry P/E33.7
Technical Analysis
TrendBearish
RSI45.4
SupportA$71.45
ResistanceA$89.47
MA 20A$80.13
MA 50A$90.23
MA 200A$140.37
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair ValueA$124.48
Target PriceA$152.85
Upside/Downside89.80%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.69
Volatility79.05%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.